Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 270-271

  Clouse, Thomas ^a   Geisler, John P ^a,b   Manahan, Kelly J ^a   Gudenkauf, Thomas J ^a   Linnemeier, Georgiann ^a   Wiemann, Michael C ^a  

^a ST VINCENT HOSPITAL   (United States)

^b Saint Vincent Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DESLORATADINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DRUG METABOLITE; FAMOTIDINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LORATADINE; METHYLPREDNISOLONE; NIZATIDINE; ONDANSETRON; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; DRUG CLEARANCE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; LETTER; NEUTROPENIA; OVARY CANCER; PREMEDICATION; PRIORITY JOURNAL; PROPHYLAXIS; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 4644234329     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.029     Document Type: Letter

References (13)

1. P.B. Desai, J.Z. Duan, Y.W. Zhu, and S. Kouzi Human liver microsomal metabolism of paclitaxel and drug interactions Eur. J. Drug Metab. Pharmacokinet. 23 1998 417 424
2. T. Cresteil, B. Monsarrat, J. Dubois, M. Sonnier, P. Alvinerie, and F. Gueritte Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structureâ€"activity relationship Drug Metab. Dispos. 30 2002 438 445
3. D.S. Sonnichsen, Q. Liu, E.G. Schuetz, J.D. Schuetz, A. Pappo, and M.V. Relling Variability in human cytochrome P450 paclitaxel metabolism J. Pharmacol. Exp. Ther. 275 1995 566 575
4. J. Hirth, P.B. Watkins, M. Strawderman, A. Schott, R. Bruno, and L.H. Baker The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance Clin. Cancer Res. 6 2000 1255 1258
5. C. Martinez, C. Albet, J.A. Agundez, E. Herrero, J.A. Carrillo, and M. Marquez Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists Clin. Pharmacol. Ther. 65 1999 369 376
6. B. Monsarat, I. Royer, M. Wright, and T. Cresteil Biotransformation of taxoids and human cytochrome P450: structureâ€"activity relationship Bull. Cancer 84 1997 125 133
7. E.K. Rowinsky, M.R. Gilbert, W.P. McGuire, D.A. Noe, L.B. Grochow, and A.A. Forastiere Sequences of taxol and cisplatin: a phase I and pharmacologic study J. Clin. Oncol. 9 1991 1692 1703
8. B. Monsarrat, E. Chatelut, I. Royer, P. Alvinerie, J. Dubois, and A. Dezeuse Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4 Drug Metab. Dispos. 26 1998 229 233
9. K. Villikka, T. Varis, J.T. Backman, P.J. Neuvonen, and K.T. Kivisto Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo Eur. J. Clin. Pharmacol. 57 2001 457 460
10. A. Sharma, and B.A. Hamelin Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view Curr. Drug Metab. 4 2003 105 129
11. M.E. Barecki, C.N. Casciano, W.W. Johnson, and R.P. Clement In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes Drug Metab. Dispos. 29 2001 1173 1175
12. K. Villikka, K.T. Kivisto, and P.J. Neuvonen The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron Clin. Pharmacol. Ther. 65 1999 377 381
13. E.L. Michalets, and C.R. Williams Drug interactions with cisapride: clinical implications Clin. Pharmacokinet. 39 2000 49 75